Tracking the CTSO option chain helps you see every strike and expiry on Cytosorbents Corp in one view, so you can quickly identify the contracts that fit your thesis and your risk. Cytosorbents Corp's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CTSO options activity at a glance. Use our scanner to monitor the CTSO option chain in real time and filter for the CTSO options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CTSO stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the CTSO option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where CTSO stock options are being actively traded and where they are not.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.
In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Cytosorbents Corp's full chain across every expiry, highlights the most liquid strikes, and lets you screen CTSO options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of CTSO stock options — let the full option chain come to you, pre-filtered and ready to trade.
